164 related articles for article (PubMed ID: 35249499)
1. Apparent Diffusion Coefficient as a Noninvasive Biomarker for the Early Response in Hepatocellular Carcinoma After Transcatheter Arterial Chemoembolization Using Drug-eluting Beads.
Li B; Zhou L; Xu A; Li Q; Xiang H; Huang Y; Peng L; Xiang K; Zhang M; Wang N
Curr Med Imaging; 2022; 18(11):1186-1194. PubMed ID: 35249499
[TBL] [Abstract][Full Text] [Related]
2. Immediate post-doxorubicin drug-eluting beads chemoembolization Mr Apparent diffusion coefficient quantification predicts response in unresectable hepatocellular carcinoma: A pilot study.
Kokabi N; Camacho JC; Xing M; Edalat F; Mittal PK; Kim HS
J Magn Reson Imaging; 2015 Oct; 42(4):981-9. PubMed ID: 25683022
[TBL] [Abstract][Full Text] [Related]
3. Transarterial Radioembolization Following Chemoembolization for Unresectable Hepatocellular Carcinoma: Response Based on Apparent Diffusion Coefficient Change is an Independent Predictor for Survival.
Klompenhouwer EG; Dresen RC; Verslype C; Laenen A; Bonne L; Vandecaveye V; Maleux G
Cardiovasc Intervent Radiol; 2018 Nov; 41(11):1716-1726. PubMed ID: 29872894
[TBL] [Abstract][Full Text] [Related]
4. Quantification of Functional MR Predicts Early Response in Post-doxorubicin Drug-Eluting Beads Chemoembolization for Hepatocellular Carcinoma.
Ou HY; Cheng YF; Chuang YH; Hsu HW; Chen CL; Lazo MZ; Weng CC; Yu CY; Tsang LL; Huang TL; Tong YS
Dig Dis Sci; 2020 Aug; 65(8):2433-2441. PubMed ID: 31732907
[TBL] [Abstract][Full Text] [Related]
5. Baseline and Early MR Apparent Diffusion Coefficient Quantification as a Predictor of Response of Unresectable Hepatocellular Carcinoma to Doxorubicin Drug-Eluting Bead Chemoembolization.
Kokabi N; Ludwig JM; Camacho JC; Xing M; Mittal PK; Kim HS
J Vasc Interv Radiol; 2015 Dec; 26(12):1777-86. PubMed ID: 26603497
[TBL] [Abstract][Full Text] [Related]
6. Conventional Versus Small Doxorubicin-eluting Bead Transcatheter Arterial Chemoembolization for Treating Barcelona Clinic Liver Cancer Stage 0/A Hepatocellular Carcinoma.
Kang YJ; Lee BC; Kim JK; Yim NY; Kim HO; Cho SB; Jeong YY
Cardiovasc Intervent Radiol; 2020 Jan; 43(1):55-64. PubMed ID: 31646378
[TBL] [Abstract][Full Text] [Related]
7. Value of Gd-EOB-DTPA-Enhanced MRI and Diffusion-Weighted Imaging in Detecting Residual Hepatocellular Carcinoma After Drug-Eluting Bead Transarterial Chemoembolization.
Liu HF; Xu YS; Liu Z; Che KY; Sheng Y; Ding JL; Zhang JG; Lei JQ; Xing W
Acad Radiol; 2021 Jun; 28(6):790-798. PubMed ID: 32414638
[TBL] [Abstract][Full Text] [Related]
8. Short-term efficacy and safety of callispheres drug-loaded microsphere embolization in primary hepatocellular carcinoma.
Li J; Wang N; Shi C; Liu Q; Song J; Ye X
J Cancer Res Ther; 2021 Jul; 17(3):733-739. PubMed ID: 34269307
[TBL] [Abstract][Full Text] [Related]
9. Apparent Diffusion Coefficient Can Predict Therapy Response of Hepatocellular Carcinoma to Transcatheter Arterial Chemoembolization.
Drewes R; Heinze C; Pech M; Powerski M; Woidacki K; Wienke A; Surov A; Omari J
Dig Dis; 2022; 40(5):596-606. PubMed ID: 34749359
[TBL] [Abstract][Full Text] [Related]
10. Diffusion-weighted imaging of hepatocellular carcinoma before and after transarterial chemoembolization: role in survival prediction and response evaluation.
Labeur TA; Runge JH; Klompenhouwer EG; Klümpen HJ; Takkenberg RB; van Delden OM
Abdom Radiol (NY); 2019 Aug; 44(8):2740-2750. PubMed ID: 31069479
[TBL] [Abstract][Full Text] [Related]
11. Correlation between SACE (Subjective Angiographic Chemoembolization Endpoint) score and tumor response and its impact on survival after DEB-TACE in patients with hepatocellular carcinoma.
Habbel VSA; Zeile M; Stavrou GA; Wacker F; Brüning R; Oldhafer KJ; Rodt T
Abdom Radiol (NY); 2019 Oct; 44(10):3463-3479. PubMed ID: 31332502
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of efficacy of transcatheter arterial chemoembolization combined with computed tomography-guided radiofrequency ablation for hepatocellular carcinoma using magnetic resonance diffusion weighted imaging and computed tomography perfusion imaging: A prospective study.
Shao GL; Zheng JP; Guo LW; Chen YT; Zeng H; Yao Z
Medicine (Baltimore); 2017 Jan; 96(3):e5518. PubMed ID: 28099329
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of Texture Analysis Parameter for Response Prediction in Patients with Hepatocellular Carcinoma Undergoing Drug-eluting Bead Transarterial Chemoembolization (DEB-TACE) Using Biphasic Contrast-enhanced CT Image Data: Correlation with Liver Perfusion CT.
Kloth C; Thaiss WM; Kärgel R; Grimmer R; Fritz J; Ioanoviciu SD; Ketelsen D; Nikolaou K; Horger M
Acad Radiol; 2017 Nov; 24(11):1352-1363. PubMed ID: 28652049
[TBL] [Abstract][Full Text] [Related]
14. mRECIST and EASL responses at early time point by contrast-enhanced dynamic MRI predict survival in patients with unresectable hepatocellular carcinoma (HCC) treated by doxorubicin drug-eluting beads transarterial chemoembolization (DEB TACE).
Prajapati HJ; Spivey JR; Hanish SI; El-Rayes BF; Kauh JS; Chen Z; Kim HS
Ann Oncol; 2013 Apr; 24(4):965-73. PubMed ID: 23223331
[TBL] [Abstract][Full Text] [Related]
15. Predictive factors for complete response of chemoembolization with drug-eluting beads (DEB-TACE) for hepatocellular carcinoma.
Vesselle G; Quirier-Leleu C; Velasco S; Charier F; Silvain C; Boucebci S; Ingrand P; Tasu JP
Eur Radiol; 2016 Jun; 26(6):1640-8. PubMed ID: 26455721
[TBL] [Abstract][Full Text] [Related]
16. Chemoembolization for hepatocellular carcinoma: 1-month response determined with apparent diffusion coefficient is an independent predictor of outcome.
Vandecaveye V; Michielsen K; De Keyzer F; Laleman W; Komuta M; Op de beeck K; Roskams T; Nevens F; Verslype C; Maleux G
Radiology; 2014 Mar; 270(3):747-57. PubMed ID: 24475816
[TBL] [Abstract][Full Text] [Related]
17. Role of diffusion-weighted imaging in evaluating therapeutic efficacy after transcatheter arterial chemoembolization for hepatocellular carcinoma.
Kubota K; Yamanishi T; Itoh S; Murata Y; Miyatake K; Yasunami H; Morio K; Hamada N; Nishioka A; Ogawa Y
Oncol Rep; 2010 Sep; 24(3):727-32. PubMed ID: 20664980
[TBL] [Abstract][Full Text] [Related]
18. Five-year outcome of conventional and drug-eluting transcatheter arterial chemoembolization in patients with hepatocellular carcinoma.
Liu YS; Lin CY; Chuang MT; Lin CY; Tsai YS; Wang CK; Ou MC
BMC Gastroenterol; 2018 Aug; 18(1):124. PubMed ID: 30075752
[TBL] [Abstract][Full Text] [Related]
19. ADC
Wu L; Xu P; Rao S; Yang L; Chen C; Liu H; Fu C; Zeng M
J Magn Reson Imaging; 2017 Sep; 46(3):820-830. PubMed ID: 28276105
[TBL] [Abstract][Full Text] [Related]
20. Prognostic value of vascular endothelial growth factor in both conventional and drug eluting beads transarterial chemoembolization for treatment of unresectable hepatocellular carcinoma in HCV patients.
Farid K; Elalfy H; Abo El-Khair SM; Elgamal H; Besheer T; Elmokadem A; Shabana W; Abed S; Elegezy M; El-Khalek AA; El-Morsy A; Negm A; Elsamanoudy AZ; El Deek B; Amer T; El-Bendary M
Expert Rev Gastroenterol Hepatol; 2020 Dec; 14(12):1203-1214. PubMed ID: 32933325
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]